Plasma proteomics of acute tubular injury.

Humans Acute Kidney Injury / blood Proteomics / methods Male Biomarkers / blood Female Middle Aged COVID-19 / blood Osteopontin / blood Tenascin / blood Kidney Tubules / metabolism Aged Adult SARS-CoV-2 Single-Cell Analysis Blood Proteins / metabolism

Journal

Nature communications

ISSN: 2041-1723

Titre abrégé: Nat Commun

Pays: England

ID NLM: 101528555

Informations de publication

Date de publication:
27 Aug 2024

Historique:

received: 13 02 2024

accepted: 05 08 2024

medline: 28 8 2024

pubmed: 28 8 2024

entrez: 27 8 2024

Statut: epublish

Résumé

The kidney tubules constitute two-thirds of the cells of the kidney and account for the majority of the organ's metabolic energy expenditure. Acute tubular injury (ATI) is observed across various types of kidney diseases and may significantly contribute to progression to kidney failure. Non-invasive biomarkers of ATI may allow for early detection and drug development. Using the SomaScan proteomics platform on 434 patients with biopsy-confirmed kidney disease, we here identify plasma biomarkers associated with ATI severity. We employ regional transcriptomics and proteomics, single-cell RNA sequencing, and pathway analysis to explore biomarker protein and gene expression and enriched biological pathways. Additionally, we examine ATI biomarker associations with acute kidney injury (AKI) in the Kidney Precision Medicine Project (KPMP) (n = 44), the Atherosclerosis Risk in Communities (ARIC) study (n = 4610), and the COVID-19 Host Response and Clinical Outcomes (CHROME) study (n = 268). Our findings indicate 156 plasma proteins significantly linked to ATI with osteopontin, macrophage mannose receptor 1, and tenascin C showing the strongest associations. Pathway analysis highlight immune regulation and organelle stress responses in ATI pathogenesis.

Identifiants

DOI: 10.1038/s41467-024-51304-x PMID: 39191768

pubmed: 39191768

doi: 10.1038/s41467-024-51304-x

pii: 10.1038/s41467-024-51304-x

doi:

Substances chimiques

Biomarkers 0

Osteopontin 106441-73-0

Tenascin 0

TNC protein, human 0

SPP1 protein, human 0

Blood Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

7368

Informations de copyright

Références

Zuk, A. & Bonventre, J. V. Acute kidney injury. Annu Rev. Med 67, 293–307 (2016).

pubmed: 26768243 pmcid: 4845743 doi: 10.1146/annurev-med-050214-013407

Hsu, R. K. & Hsu, C. Y. The role of acute kidney injury in chronic kidney disease. Semin Nephrol. 36, 283–292 (2016).

pubmed: 27475659 pmcid: 4979984 doi: 10.1016/j.semnephrol.2016.05.005

Chevalier, R. L. The proximal tubule is the primary target of injury and progression of kidney disease: role of the glomerulotubular junction. Am. J. Physiol. Ren. Physiol. 311, F145–F161 (2016).

doi: 10.1152/ajprenal.00164.2016

Balzer, M. S., Rohacs, T. & Susztak, K. How many cell types are in the kidney and what do they do? Annu Rev. Physiol. 84, 507–531 (2022).

pubmed: 34843404 doi: 10.1146/annurev-physiol-052521-121841

Matovinović, M. S. 1. Pathophysiology and classification of kidney diseases. Ejifcc 20, 2–11 (2009).

pubmed: 27683321 pmcid: 4975264

Gilbert, R. E. & Cooper, M. E. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 56, 1627–1637 (1999).

pubmed: 10571771 doi: 10.1046/j.1523-1755.1999.00721.x

Sun, M. et al. Clinical characteristics and prognosis of patients with idiopathic membranous nephropathy with kidney tubulointerstitial damage. Ren. Fail 45, 2205951 (2023).

pubmed: 37125531 pmcid: 10134950 doi: 10.1080/0886022X.2023.2205951

Moeckel, G. W. Pathologic perspectives on acute tubular injury assessment in the kidney biopsy. Semin Nephrol. 38, 21–30 (2018).

pubmed: 29291758 doi: 10.1016/j.semnephrol.2017.09.003

Wen, Y., Yang, C., Menez, S. P., Rosenberg, A. Z. & Parikh, C. R. A systematic review of clinical characteristics and histologic descriptions of acute tubular injury. Kidney Int Rep. 5, 1993–2001 (2020).

pubmed: 33163720 pmcid: 7609907 doi: 10.1016/j.ekir.2020.08.026

Gaut, J. P. & Liapis, H. Acute kidney injury pathology and pathophysiology: a retrospective review. Clin. Kidney J. 14, 526–536 (2021).

pubmed: 33623675 doi: 10.1093/ckj/sfaa142

Muiru, A. N. et al. Risk for chronic kidney disease progression after acute kidney injury: findings from the chronic renal insufficiency cohort study. Ann. Intern Med 176, 961–968 (2023).

pubmed: 37429030 pmcid: 10829039 doi: 10.7326/M22-3617

Sabbisetti, V. S. et al. Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. J. Am. Soc. Nephrol. 25, 2177–2186 (2014).

pubmed: 24904085 pmcid: 4178434 doi: 10.1681/ASN.2013070758

Waikar, S. S. et al. Relationship of proximal tubular injury to chronic kidney disease as assessed by urinary kidney injury molecule-1 in five cohort studies. Nephrol. Dial. Transpl. 31, 1460–1470 (2016).

doi: 10.1093/ndt/gfw203

Niewczas, M. A. et al. A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nat. Med 25, 805–813 (2019).

pubmed: 31011203 pmcid: 6508971 doi: 10.1038/s41591-019-0415-5

Isakova, T. Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 21, 334–340 (2012).

pubmed: 22487610 pmcid: 3353875 doi: 10.1097/MNH.0b013e328351a391

Bonomini, M. et al. Proteomic investigations into hemodialysis therapy. Int J. Mol. Sci. 16, 29508–29521 (2015).

pubmed: 26690416 pmcid: 4691132 doi: 10.3390/ijms161226189

Tsalik, E. L. et al. Renal systems biology of patients with systemic inflammatory response syndrome. Kidney Int 88, 804–814 (2015).

pubmed: 25993322 pmcid: 4591107 doi: 10.1038/ki.2015.150

Feldreich, T. et al. Circulating proteins as predictors of cardiovascular mortality in end-stage renal disease. J. Nephrol. 32, 111–119 (2019).

pubmed: 30499038 doi: 10.1007/s40620-018-0556-5

Schmidt, I. M. et al. Circulating plasma biomarkers in biopsy-confirmed kidney disease. Clin. J. Am. Soc. Nephrol. 17, 27–37 (2022).

pubmed: 34759008 pmcid: 8763150 doi: 10.2215/CJN.09380721

Carlsson, A. C. et al. Use of proteomics to investigate kidney function decline over 5 years. Clin. J. Am. Soc. Nephrol. 12, 1226–1235 (2017).

pubmed: 28784837 pmcid: 5544512 doi: 10.2215/CJN.08780816

Glorieux, G. et al. New insights in molecular mechanisms involved in chronic kidney disease using high-resolution plasma proteome analysis. Nephrol. Dial. Transpl. 30, 1842–1852 (2015).

doi: 10.1093/ndt/gfv254

Kammer, M. et al. Integrative analysis of prognostic biomarkers derived from multiomics panels helps discrimination of chronic kidney disease trajectories in people with type 2 diabetes. Kidney Int 96, 1381–1388 (2019).

pubmed: 31679767 doi: 10.1016/j.kint.2019.07.025

Azuaje F., Kim S. Y., Perez Hernandez D., Dittmar G. Connecting Histopathology Imaging and Proteomics in Kidney Cancer through Machine Learning. J Clin Med. 2019;8.

Sethi, S. et al. Glomeruli of dense deposit disease contain components of the alternative and terminal complement pathway. Kidney Int. 75, 952–960 (2009).

pubmed: 19177158 pmcid: 2738640 doi: 10.1038/ki.2008.657

Chawla, L. S., Eggers, P. W., Star, R. A. & Kimmel, P. L. Acute kidney injury and chronic kidney disease as interconnected syndromes. N. Engl. J. Med 371, 58–66 (2014).

pubmed: 24988558 pmcid: 9720902 doi: 10.1056/NEJMra1214243

Nowak, N. et al. Increased plasma kidney injury molecule-1 suggests early progressive renal decline in non-proteinuric patients with type 1 diabetes. Kidney Int 89, 459–467 (2016).

pubmed: 26509588 pmcid: 4848189 doi: 10.1038/ki.2015.314

Assarsson, E. et al. Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One 9, e95192 (2014).

pubmed: 24755770 pmcid: 3995906 doi: 10.1371/journal.pone.0095192

Schmidt, I. M. et al. Plasma kidney injury molecule 1 in CKD: findings from the Boston Kidney Biopsy Cohort and CRIC studies. Am. J. Kidney Dis. 79, 231–243.e231 (2022).

pubmed: 34175376 doi: 10.1053/j.ajkd.2021.05.013

Mansour, S. G. et al. Uromodulin to osteopontin ratio in deceased donor urine is associated with kidney graft outcomes. Transplantation 105, 876–885 (2021).

pubmed: 32769629 pmcid: 8805736 doi: 10.1097/TP.0000000000003299

Xie, Y. et al. Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int 60, 1645–1657 (2001).

pubmed: 11703581 doi: 10.1046/j.1523-1755.2001.00032.x

Khamissi, F. Z. et al. Identification of kidney injury released circulating osteopontin as causal agent of respiratory failure. Sci. Adv. 8, eabm5900 (2022).

pubmed: 35213222 pmcid: 8880785 doi: 10.1126/sciadv.abm5900

Lorenzen, J. M. et al. Osteopontin predicts survival in critically ill patients with acute kidney injury. Nephrol. Dial. Transpl. 26, 531–537 (2011).

doi: 10.1093/ndt/gfq498

Steinbrenner, I. et al. Association of osteopontin with kidney function and kidney failure in chronic kidney disease patients: the GCKD study. Nephrol. Dial. Transpl. 38, 1430–1438 (2023).

doi: 10.1093/ndt/gfac173

Zhu, H. et al. Tenascin-C promotes acute kidney injury to chronic kidney disease progression by impairing tubular integrity via αvβ6 integrin signaling. Kidney Int 97, 1017–1031 (2020).

pubmed: 32245660 pmcid: 8112450 doi: 10.1016/j.kint.2020.01.026

LeBleu, V. S. et al. Identification of human epididymis protein-4 as a fibroblast-derived mediator of fibrosis. Nat. Med 19, 227–231 (2013).

pubmed: 23353556 pmcid: 4457508 doi: 10.1038/nm.2989

Wan, J. et al. Elevated serum concentrations of HE4 as a novel biomarker of disease severity and renal fibrosis in kidney disease. Oncotarget 7, 67748–67759 (2016).

pubmed: 27589683 pmcid: 5356516 doi: 10.18632/oncotarget.11682

Chen, P., Yang, Q., Li, X. & Qin, Y. Potential association between elevated serum human epididymis protein 4 and renal fibrosis: A systemic review and meta-analysis. Med. (Baltim.) 96, e7824 (2017).

doi: 10.1097/MD.0000000000007824

Ihara, K. et al. Profibrotic circulating proteins and risk of early progressive renal decline in patients with type 2 diabetes with and without albuminuria. Diabetes Care 43, 2760–2767 (2020).

pubmed: 32887710 pmcid: 7576423 doi: 10.2337/dc20-0630

Schmidt I. M., et al. Plasma Kidney Injury Molecule 1 in CKD: Findings From the Boston Kidney Biopsy Cohort and CRIC Studies. Am J Kidney Dis. 2021).

Matsuhashi, T. et al. Mitochonic Acid 5 (MA-5) Facilitates ATP Synthase Oligomerization and Cell Survival in Various Mitochondrial Diseases. EBioMedicine 20, 27–38 (2017).

pubmed: 28579242 pmcid: 5478234 doi: 10.1016/j.ebiom.2017.05.016

Fujita, Y., Ito, M. & Ohsawa, I. Mitochondrial stress and GDF15 in the pathophysiology of sepsis. Arch. Biochem Biophys. 696, 108668 (2020).

pubmed: 33188737 doi: 10.1016/j.abb.2020.108668

Perez-Gomez, M. V. et al. Urinary Growth Differentiation Factor-15 (GDF15) levels as a biomarker of adverse outcomes and biopsy findings in chronic kidney disease. J. Nephrol. 34, 1819–1832 (2021).

pubmed: 33847920 doi: 10.1007/s40620-021-01020-2

Valiño-Rivas, L. et al. Growth differentiation factor-15 preserves Klotho expression in acute kidney injury and kidney fibrosis. Kidney Int 101, 1200–1215 (2022).

pubmed: 35337892 doi: 10.1016/j.kint.2022.02.028

Zhou, Z. et al. Circulating GDF-15 in relation to the progression and prognosis of chronic kidney disease: A systematic review and dose-response meta-analysis. Eur. J. Intern Med 110, 77–85 (2023).

pubmed: 36740468 doi: 10.1016/j.ejim.2023.01.026

Delrue, C., Speeckaert, R., Delanghe, J. R. & Speeckaert, M. M. Growth differentiation factor 15 (GDF-15) in kidney diseases. Adv. Clin. Chem. 114, 1–46 (2023).

pubmed: 37268330 doi: 10.1016/bs.acc.2023.02.003

Luan, H. H. et al. GDF15 is an inflammation-induced central mediator of tissue tolerance. Cell 178, 1231–1244.e1211 (2019).

pubmed: 31402172 pmcid: 6863354 doi: 10.1016/j.cell.2019.07.033

Abulizi, P. et al. Growth differentiation factor-15 deficiency augments inflammatory response and exacerbates septic heart and renal injury induced by lipopolysaccharide. Sci. Rep. 7, 1037 (2017).

pubmed: 28432312 pmcid: 5430818 doi: 10.1038/s41598-017-00902-5

Wang, D. et al. GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease. Nat. Rev. Endocrinol. 17, 592–607 (2021).

pubmed: 34381196 doi: 10.1038/s41574-021-00529-7

Sen, T. et al. Association between circulating GDF-15 and cardio-renal outcomes and effect of canagliflozin: results from the CANVAS trial. J. Am. Heart Assoc. 10, e021661 (2021).

pubmed: 34854308 pmcid: 9075362 doi: 10.1161/JAHA.121.021661

Liu, J. et al. Renoprotective and immunomodulatory effects of GDF15 following AKI invoked by ischemia-reperfusion injury. J. Am. Soc. Nephrol. 31, 701–715 (2020).

pubmed: 32034106 pmcid: 7191932 doi: 10.1681/ASN.2019090876

Kiernan, E. et al. Alterations in the circulating proteome associated with albuminuria. J. Am. Soc. Nephrol. 34, 1078–1089 (2023).

pubmed: 36890639 pmcid: 10278823 doi: 10.1681/ASN.0000000000000108

Grams, M. E. et al. Proteins associated with risk of kidney function decline in the general population. J. Am. Soc. Nephrol. 32, 2291–2302 (2021).

pubmed: 34465608 pmcid: 8729856 doi: 10.1681/ASN.2020111607

Renné, T. The vascular side of plasma kallikrein. Blood 125, 589–590 (2015).

pubmed: 25614637 doi: 10.1182/blood-2014-11-609016

Härma, M. A. et al. Decreased plasma kallikrein activity is associated with reduced kidney function in individuals with type 1 diabetes. Diabetologia 63, 1349–1354 (2020).

pubmed: 32270254 pmcid: 7286847 doi: 10.1007/s00125-020-05144-1

Cheng, Y. et al. Genetics of osteopontin in patients with chronic kidney disease: The German Chronic Kidney Disease study. PLoS Genet 18, e1010139 (2022).

pubmed: 35385482 pmcid: 9015153 doi: 10.1371/journal.pgen.1010139

Moradi, N. et al. Serum levels of CTRP3 in diabetic nephropathy and its relationship with insulin resistance and kidney function. PLoS One 14, e0215617 (2019).

pubmed: 31009504 pmcid: 6476508 doi: 10.1371/journal.pone.0215617

Chen, X. et al. C1q/tumor necrosis factor-related protein-3 improves renal fibrosis via inhibiting notch signaling pathways. J. Cell Physiol. 234, 22352–22364 (2019).

pubmed: 31074042 doi: 10.1002/jcp.28801

Du, C. et al. C1q/tumour necrosis factor-related protein-3 alleviates high-glucose-induced lipid accumulation and necroinflammation in renal tubular cells by activating the adenosine monophosphate-activated protein kinase pathway. Int J. Biochem Cell Biol. 149, 106247 (2022).

pubmed: 35753650 doi: 10.1016/j.biocel.2022.106247

Inagi, R. The implication of organelle cross talk in AKI. Nephron 144, 634–637 (2020).

pubmed: 32702704 doi: 10.1159/000508639

Srivastava, A. et al. The prognostic value of histopathologic lesions in native kidney biopsy specimens: results from the Boston Kidney Biopsy Cohort study. J. Am. Soc. Nephrol. 29, 2213–2224 (2018).

pubmed: 29866798 pmcid: 6065095 doi: 10.1681/ASN.2017121260

de Boer, I. H. et al. Rationale and design of the kidney precision medicine project. Kidney Int 99, 498–510 (2021).

pubmed: 33637194 pmcid: 8330551 doi: 10.1016/j.kint.2020.08.039

Wright, J. D. et al. The ARIC (Atherosclerosis Risk In Communities) study: JACC Focus Seminar 3/8. J. Am. Coll. Cardiol. 77, 2939–2959 (2021).

pubmed: 34112321 pmcid: 8667593 doi: 10.1016/j.jacc.2021.04.035

Sathe, N. A. et al. Biomarker signatures of severe acute kidney injury in a critically Ill cohort of covid-19 and non-covid-19 acute respiratory illness. Crit. Care Explor 5, e0945 (2023).

pubmed: 37457915 pmcid: 10348733 doi: 10.1097/CCE.0000000000000945

Gold, L. et al. Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS One 5, e15004 (2010).

pubmed: 21165148 pmcid: 3000457 doi: 10.1371/journal.pone.0015004

Grams, M. E. et al. Performance and limitations of administrative data in the identification of AKI. Clin. J. Am. Soc. Nephrol. 9, 682–689 (2014).

pubmed: 24458075 pmcid: 3974361 doi: 10.2215/CJN.07650713

Inker, L. A. et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N. Engl. J. Med 385, 1737–1749 (2021).

pubmed: 34554658 pmcid: 8822996 doi: 10.1056/NEJMoa2102953

Lake, B. B. et al. An atlas of healthy and injured cell states and niches in the human kidney. Nature 619, 585–594 (2023).

pubmed: 37468583 pmcid: 10356613 doi: 10.1038/s41586-023-05769-3

Barwinska D., et al. Molecular characterization of the human kidney interstitium in health and disease. Sci Adv. 2021;7.

Mootha, V. K. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet 34, 267–273 (2003).

pubmed: 12808457 doi: 10.1038/ng1180

Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).

pubmed: 16199517 pmcid: 1239896 doi: 10.1073/pnas.0506580102